Today's Information |
Provided by: Medigen Vaccine Biologics Corporation | |||||
SEQ_NO | 2 | Date of announcement | 2022/06/08 | Time of announcement | 17:28:10 |
Subject | Additional update on clinical development on MVC COVID-19 vaccine in the WHO COVID-19 Solidarity Trial Vaccines (Supplementary Announcement) | ||||
Date of events | 2022/05/13 | To which item it meets | paragraph 53 | ||
Statement | 1.Date of occurrence of the event:2022/05/13 2.Company name:MEDIGEN VACCINE BIOLOGICS CORPORATION 3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office 4.Reciprocal shareholding ratios:non applicable 5.Cause of occurrence: MVC COVID-19 Vaccine is a vaccine candidates included in WHO's Solidarity Trial Vaccines (STV), a multi center, multi vaccine, adaptive, shared placebo, event driven, individually randomized controlled Phase 3 clinical trial. Recruitment for STV for the purposes of MVC COVID-19 Vaccine has been completed across three countries, Colombia, Mali and the Philippines. To date, approximately 18,000 participants have been enrolled for the evaluation of MVC COVID-19 Vaccine. Nearly all participants have completed their two dose regimen of either placebo or vaccine. And the study is in the process of data analysis stage. Based on the study design, once participants have completed their two dose regimen, the data will be analyzed by two independent statisticians. When the statisticians have provided their analysis, this clinical data will be further evaluated by a panel of experts in the STV steering committee. Upon completion of analysis of the interim data, the results will be published for the review by the scientific community and public at large. The announcement of the publication will be provided by WHO. 6.Countermeasures:None 7.Any other matters that need to be specified: The update of the solidarity trial is due to the WHO mentioned the progress of the trial in the meeting when the company participated in the meeting. After the meeting, with the consent of the WHO, the company announced it by a press release. If there is any update in the future, except to the announcement in MOPS, others will be made on the company's official website. |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Medigen Vaccine Biologics Corporation published this content on 08 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2022 09:41:09 UTC.